The use of physiologically acceptable enzyme mixtures having lipolytic, proteolytica and amylolytic activity, of microbial or animal origin, preferably digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the treatment of diabetes. The invention also relates to the production of pharmaceutical compositions suitable for such treatment. A preferred variant of the invention relates to use of this enzyme mixture having lipolytic, proteolytic and amylolytic activity, especially digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the adjuvant treatment of type I or type II diabetes mellitus.
